Literature DB >> 9549491

Imaging axonal damage of normal-appearing white matter in multiple sclerosis.

L Fu1, P M Matthews, N De Stefano, K J Worsley, S Narayanan, G S Francis, J P Antel, C Wolfson, D L Arnold.   

Abstract

The current study was designed to determine the relative distribution of decreases of N-acetylasparate (NAA), a marker of axonal damage, between lesions and normal-appearing white matter of patients with established multiple sclerosis and to test for associations between changes in the ratio of NAA to creatine/phosphocreatine (NAA:Cr) in those compartments and changes in disability. Data were collected from a 30-month longitudinal study of 28 patients with either a relapsing course with partial remissons and no progression between attacks (relapsing/remitting) (11 patients) or a course of progressively increasing disability, following a period of relapsing/remitting disease (secondary progressive) (17 patients). Proton magnetic resonance spectroscopic imaging (MRSI) and conventional MRI examinations were performed at 6-8-month intervals with concurrent clinical assessments of disability. General linear models were used to test associations between MRSI, MRI, lesion volume and clinical data. Analysis confirmed that the NAA:Cr ratio is lower in lesions than in the normal-appearing white matter (-15.3% in relapsing/remitting multiple sclerosis and -8.8% in secondary progressive multiple sclerosis). The lower NAA:Cr ratio per unit lesion volume previously observed for secondary progressive relative to relapsing/remitting patients was found to result from a lower ratio (8.2%, P < 0.01) in the normal-appearing white matter rather than from any differences within lesions. The importance of changes in the normal-appearing white matter was emphasized further with the observation that the NAA:Cr ratio in the normal-appearing white matter accounted for most of the observed 15.6% (P < 0.001) decrease in the NAA:Cr ratio in the brains of relapsing/remitting patients over the period of study. The decrease in the NAA:Cr ratio in normal-appearing white matter correlated strongly (P < 0.001) with changes in disability in the relapsing/remitting subgroup. These results add to data suggesting that axonal damage or loss may be responsible for functional impairments in multiple sclerosis. The accumulation of secondary axonal damage in the normal-appearing white matter may be of particular significance for understanding chronic disability in this disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9549491     DOI: 10.1093/brain/121.1.103

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  88 in total

1.  Axonal loss results in spinal cord atrophy, electrophysiological abnormalities and neurological deficits following demyelination in a chronic inflammatory model of multiple sclerosis.

Authors:  D B McGavern; P D Murray; C Rivera-Quiñones; J D Schmelzer; P A Low; M Rodriguez
Journal:  Brain       Date:  2000-03       Impact factor: 13.501

Review 2.  Neurological rehabilitation: from mechanisms to management.

Authors:  A J Thompson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-12       Impact factor: 10.154

3.  Analysis of normal-appearing white matter in multiple sclerosis: comparison of diffusion tensor MR imaging and magnetization transfer imaging.

Authors:  A C Guo; V L Jewells; J M Provenzale
Journal:  AJNR Am J Neuroradiol       Date:  2001 Nov-Dec       Impact factor: 3.825

4.  Brain imaging: the NMR revolution. Interview by Clare Thompson.

Authors:  J W Prichard; J R Alger; R Turner
Journal:  BMJ       Date:  1999-11-13

Review 5.  The Role of Advanced Magnetic Resonance Imaging Techniques in Multiple Sclerosis Clinical Trials.

Authors:  Kedar R Mahajan; Daniel Ontaneda
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

6.  MR imaging and proton spectroscopy of neuronal injury in late-onset GM2 gangliosidosis.

Authors:  Matilde Inglese; Annette O Nusbaum; Gregory M Pastores; John Gianutsos; Edwin H Kolodny; Oded Gonen
Journal:  AJNR Am J Neuroradiol       Date:  2005-09       Impact factor: 3.825

Review 7.  Imaging of multiple sclerosis: role in neurotherapeutics.

Authors:  Rohit Bakshi; Alireza Minagar; Zeenat Jaisani; Jerry S Wolinsky
Journal:  NeuroRx       Date:  2005-04

8.  Axonal degeneration and progressive neurologic disability in multiple sclerosis.

Authors:  Carl Bjartmar; Bruce D Trapp
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

9.  Standardized, reproducible, high resolution global measurements of T1 relaxation metrics in cases of multiple sclerosis.

Authors:  Radhika Srinivasan; Roland Henry; Daniel Pelletier; Sarah Nelson
Journal:  AJNR Am J Neuroradiol       Date:  2003-01       Impact factor: 3.825

Review 10.  The pathological spectrum of CNS inflammatory demyelinating diseases.

Authors:  Wei Hu; Claudia F Lucchinetti
Journal:  Semin Immunopathol       Date:  2009-09-25       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.